arrow
M

Matthias P. Ebert

Heidelberg University
H指数:46
被引数:7,169

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group

既往与同期糖皮质激素和抗生素治疗对免疫治疗疗效的差异化影响——德国AIO研究组RAMONA、INTEGA、OPTIM、ELDORANDO、FORCE、TITAN-RCC和TITAN-TCC试验的合并分析

2026-05-190
OAAI
Real-World Outcomes of Ivosidenib in IDH1-Mutant Biliary Tract Cancer: A Multicenter Retrospective Analysis and Comparison with the TrinetX Database

ivosidenib在IDH1突变胆道癌中的真实世界疗效:一项多中心回顾性分析并与TrinetX数据库的比较

2026-04-200
OAAI
Bevacizumab for Metastatic Colorectal Cancer with Chromosomal Instability: Cost-Effectiveness Analysis for a Novel Precision Treatment Approach in Germany, Ireland and Spain

贝伐珠单抗用于染色体不稳定性转移性结直肠癌:德国、爱尔兰和西班牙一种新型精准治疗方法的成本效益分析

2026-02-040
PRE
Erratum: Follistatin-controlled activin-HNF4α-coagulation factor axis in liver progenitor cells determines outcome of acute liver failure

勘误:Follistatin调控的activin-HNF4α-凝血因子轴在肝祖细胞中决定急性肝衰竭的结局

2025-11-030
PRE
Radiomics-based prediction of HCC response to atezolizumab/bevacizumab

基于放射组学的预测HCC对阿替利珠单抗/贝伐珠单抗的应答

2025-10-010
OAAI
Targeted reactivation of the novel tumor suppressor DAPK1, an upstream regulator of p53, in high-grade serous ovarian cancer by mRNA liposomes reduces viability and enhances drug sensitivity in preclinical models

通过mRNA脂质体靶向再激活新型肿瘤抑制因子DAPK1(p53的上游调节因子),在高级别浆液性卵巢癌中可降低预临床试验模型的细胞活力并增强药物敏感性。

2025-05-200
OAAI
Evaluation of four chatbots in autoimmune liver disease: A comparative analysis

四种聊天机器人在自身免疫性肝病中的评估: 比较分析

2025-01-012
PRE
The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance

免疫球蛋白超家族配体B7H6使T细胞对NK细胞监视的反应

2024-05-034
PRE
Intestinal BMP-9 locally upregulates FGF19 and is down-regulated in obese patients with diabetes
2023-06-015
OAAI